Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Profit After Tax (2020 - 2025)

Foghorn Therapeutics has reported Profit After Tax over the past 6 years, most recently at -$21.7 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$21.7 million for Q4 2025, down 11.1% from a year ago — trailing twelve months through Dec 2025 was -$74.3 million (up 14.24% YoY), and the annual figure for FY2025 was -$74.3 million, up 14.22%.
  • Profit After Tax for Q4 2025 was -$21.7 million at Foghorn Therapeutics, down from -$15.8 million in the prior quarter.
  • Over the last five years, Profit After Tax for FHTX hit a ceiling of -$14.3 million in Q3 2023 and a floor of -$30.5 million in Q1 2023.
  • Median Profit After Tax over the past 5 years was -$23.6 million (2021), compared with a mean of -$23.5 million.
  • Biggest five-year swings in Profit After Tax: crashed 64.75% in 2021 and later skyrocketed 44.33% in 2023.
  • Foghorn Therapeutics' Profit After Tax stood at -$29.1 million in 2021, then rose by 0.82% to -$28.9 million in 2022, then grew by 16.54% to -$24.1 million in 2023, then rose by 19.11% to -$19.5 million in 2024, then dropped by 11.1% to -$21.7 million in 2025.
  • The last three reported values for Profit After Tax were -$21.7 million (Q4 2025), -$15.8 million (Q3 2025), and -$17.9 million (Q2 2025) per Business Quant data.